A Phase IIIb, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Extension Trial to Evaluate the Safety and Tolerability of Oral Cladribine in Subjects With Relapsing-Remitting Multiple Sclerosis Who Have Completed Trial 25643 (CLARITY)
收藏DataCite Commons2026-04-29 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00013042/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this extension trial was to further evaluate the safety and tolerability of oral cladribine in subjects who have previously completed treatment within Trial 25643 (CLARITY). This trial also explored clinical benefit of prolonged 192-week versus 96-week treatment.
提供机构：
Vivli
创建时间：
2026-04-29
